...and it's not for no reason. This company has anticancer drugs on the market, orphan drug statuses, and groundbreaking drugs in the pipeline in late phase III trials.
People have to realize this stock was beaten down unfairly. It's on the naked short list (illegally shorted into the ground).
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.